Saturday, July 21, 2007

Solgar Vitamin and Herb Enters Into Exclusive Trademark Licensing Agreement with Optigenex Inc. to Brand, Market and Distribute AC-11(R) as a Natural

- Optigenex Inc. announced today the signing of an Exclusive Trademark Licensing Agreement with Solgar Vitamin and Herb to market and sell AC-11(R) exclusively through the Health Food and Specialty Food Sales Channel in the territories of North America, Great Britain, South Africa, New Zealand and other E.U. Territories. Under the terms of the agreement, Solgar plans to brand AC-11(R) utilizing Optigenex's registered trademark to present a new category of dietary supplement under its prestigious Gold Label line at the Natural Products Association Market Place Trade Show in Las Vegas on July 20, 2007. With the signing of this agreement, Solgar will be the first major company to actively market an AC-11(R) branded nutraceutical product. Among the unique qualities of AC-11(R) is the clinical and scientific validated properties of this proprietary extract. In third party studies, AC-11 has been shown to help the body's natural ability to repair damage to DNA due to multiple causes including: harmful effects of UV radiation from over exposure to the sun, stress, environmental pollution and other toxins. AC-11(R) has also been established as an inhibitor of pro-inflammatory compounds and has demonstrated effectiveness as a natural immune supporter and as an anti-tumor agent.

Rand Skolnick, President and CEO of Solgar Vitamin and Herb, commented, "We are excited to be working with Optigenex to provide a new platform technology of natural DNA repair dietary supplements to our customers. The future of healthy aging and wellness will be directly related to our own ability to support and maintain the integrity of our DNA and its expression. Solgar looks forward to becoming the market leader in this area of alternative health care while providing our customers with sound choices and a greater personal role in maintaining their own health."

source:money.cnn.com

No comments: